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Implication for health policy/practice/research/medical education:
It is possible that, magnesium aggravates H. pylori infection in kidney transplant patients through the mechanisms like hemodialysis, 
which we had reported previously. However, more studies are necessary to prove the association of magnesium with H. pylori 
infection in renal transplant patients and finding the clinical relevance of our findings.
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Introduction
Helicobacter pylori (H. pylori) infection is detected to 
be closely associated with upper gastrointestinal disease, 
like gastro-duodenal ulcers, chronic gastritis, and gastric 
cancer (1,2). Moreover, renal transplant patients often 
complain of digestive symptoms. In fact, most renal 
transplant recipients will have various gastrointestinal 
complications which are mostly due to opportunistic 
infections but can also be caused by immunosuppressive 
drug regimens (2-4). A renal transplant recipient may be 
affected by mucosa associated lymphoid tissue which is 
a gastric lymphoma (2-5). This lymphoma may respond 
to H. pylori eradication therapy (3-6). H. pylori, infection 
is a major worldwide health problem, with an estimated 
global prevalence of approximately 50% too (4-6). H. 
pylori is a spiral-shaped gram negative flagellate bacterium 
that occupies the mucosal layer of the gastric epithelium 
(1-3). Diagnosis of H. pylori infection can be achieved 
with both invasive and noninvasive tests. Noninvasive 
evaluations for the diagnosis of H. pylori infection, which 
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are based on analysis of samples of breath, blood, or stool, 
have been progressed (2-5). Serological tests are unable 
to discriminate active from pastinfection. Noninvasive 
tests are valuable for primary diagnosis, when a treatment 
indication exists, or to observe treatment success or 
failure. Urease breath test (UBT), could be used both safely 
and cost effectively to screen H. pylori-positive patients 
and has been shown to be excellent in performing (1-4). 
The prevalence of H. pylori infection is associated the 
socioeconomic status and living conditions during early 
life (2,3). However, few studies are available regarding the 
various promoting factors of H. pylori infection in kidney 
disease patients especially renal transplant individuals. 
Previously, we had shown the positive association of H. 
pylori–IgG antibody with plasma magnesium in a group 
of maintenance hemodialysis patients (7). 
Objectives
This study was therefore conducted to examine the 
association of serum magnesium with H. pylori infection 
among kidney transplant patients.
Patients and Methods
Patients
This cross-sectional investigation was conducted on a 
group of stable kidney transplant patients. Patients were 
studied between September 20013 to January 2014. The 
study was carried out in the clinic of Shahrekord University 
of Medical Sciences of Iran. All patients signed the consent 
form for participation. All patients were examined and 
their medical history, including the length of time they 
received a kidney for transplantation and their treatment 
protocols were recorded. The basic immunosuppressive 
regimen of the recipients contained of a combination of 
cyclosporine at a mean dose of 190 ± 60 mg/d (median: 
200 mg/d) and prednisolone 7.5 mg/d and mycophenolate 
mofetil a dose of 1500 ± 500 mg/d (median: 1500 
mg/d). Exclusion criteria included, any active or chronic 
infection, intake of any antibiotic or non-steroidal anti-
inflammatory drugs during the past two months and 
taking drugs that affect gastric acid production during the 
past two months, like, antacids, proton pump inhibitors 
and H2 receptor antagonists and also the presence of acute 
rejection (8-10). Body mass index (BMI) was calculated 
by weight in kilograms/height in square meters (11).
Laboratory methods
Peripheral venous blood samples were collected for 
biochemical analysis after an overnight fast, including 
serum creatinine, blood urea nitrogen (BUN), albumin 
(Alb), serum magnesium (Mg), phosphorus (P), calcium 
(Ca) and alkaline phosphatase (ALP), using standard 
kits after an overnight fast. The estimated glomerular 
filtration rate (eGFR) values were calculated according 
to the modification of diet in renal diseases (MDRD) 
formula (12,13). Serum H. pylori-specific IgG antibody 
titer was measured by the enzyme linked immunosorbent 
assay (ELISA) method using monobind kit (USA) 
(normal range<20 U/mL). Intact parathormone (iPTH) 
using Cobas kit, (Roche) was measured by ELISA method 
(normal range of values is 15 pg/mL to 65 pg/mL). Also 
urea breath test (UBT) using heliprobe breathcard™/
Helikit; (Sweden) was conducted for patients. 
Ethical issues
The study was approved by the institutional ethics 
committee of Shahrekord University of Medical Sciences. 
A written informed consent was obtained from all the 
study participants.
Statistical analysis
The data was analyzed with Stata 12 (Stata Corporation, 
College Station, Texas) using descriptive analysis, 
proportion, mean and standard deviation, confidence 
interval 95%, Shapiro-Francia W’ test, Student’s t-test, 
ANOVA, Fisher’s exact and Pearson’s Chi-squared test. 
For normalization of the data, logarithms of 10 or SE/
Robust were used. P values of less than 0.05 was assume d 
to be significant (p<0.05).
Results
A total of 50 cases was enrolled to the study. The age of 
the patients ranged from 28 to 72 with the mean (SD) 
age of 47.4 ±10.4 years. Demographic and biochemical 
data of the study patients was shown in Table 1. 4% of the 
patients were under 30 years old, 50% between 31-49 years 
old, and 46% over 50-74 years old. 56% of the patients (n: 
28) were male. Mean (SD) of kidney, transplantation in 
patients was 43.3 ± 20.5 months (range: 8-80). Patients 
stratified by time after they received a transplanted kidney 
8% less than 12 months, 38% between 12-36 months, 42% 
between 37-72 months and 12% between 73 to 80 months. 
Comparison sex and duration of kidney transplantation 
in the study patients was shown in Table 2. Mean serum 
magnesium value of the patients was 1.98 ± 0.62 mg/dl 
and mean of serum creatinine value was 1.36 ± 0.4 mg/
dl. In this study, positive significant correlation between 
serum magnesium and creatinine in total patients was 
seen (r= 0.32, p= 0.02). Positive significant correlation 
between serum magnesium and duration of kidney 
transplantation in positive H. pylori patients was detected 
too (r= 0.82, p= 0.0001). According to UBT and IgG tests, 
the prevalence of positive H. pylori in patients was 38 % 
and 34% respectively. Mean (SD) serum magnesium of 
the patients without H. pylori was 1.75 ± 0.65 mg/dl and 
this value in patients positive H. pylori was 2.35 ± 0.3 mg/
dl. Serum magnesium level in positive H. pylori patients 
was more than negative H. pylori patients (p=0.0005). 
The mean of creatinine in negative and positive H. 
pylori patients was 1.72 ± 0.3 and 1.15 ± 0.2 respectively. 
Serum creatinine in positive H. pylori patients was more 
than negative H. pylori patients (p=0.001). Mean (SD) of 
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biochemical factors was shown in Table 3. In this study 
population, there was no significant difference in serum 
intact PTH, calcium, alkaline phosphatase, albumin levels 
and eGFR, and also BMI between males and females or 
H. pylori positive and H. pylori negative subjects (p>0.5). 
Correlation coefficients between serum magnesium and 
others parameters were shown in Table 4. 
Discussion
In the present study, we found that, the value of serum 
magnesium level in positive H. pylori patients was 
more than negative H. pylori patients. To understand, 
the aggravating factors of H. pylori infection in chronic 
kidney disease, especially in hemodialysis patients, we 
previously conducted a study on 44 hemodialysis patients. 
At this investigation, we detected a significant positive 
correlation of H. pylori antibody with serum magnesium 
(7). The results of this study suggested the association of 
serum magnesium with the H. pylori infection (7). We also 
conducted another study on 94 type II diabetic patients who 
had a mean creatinine clearance value of 62 ± 23 cc/min. 
In this investigation, there was no significant correlation 
of serum anti-H. pylori specific antibody titer with serum 
magnesium level (14). It is evident that magnesium ion 
acquisition is necessary for H. pylori (7,15). We assumed 
that, the elevated serum magnesium level in hemodialysis 
Table 1. Demographic and biochemical data of the study patients
Parameter Mean ± SD Median Minimum Maximum
Age (years) 47.4 ± 10.4 47 28 72
Serum creatinine (mg/dl) 1.36 ± 0.4 1.3 0.5 2.2
Serum magnesium (mg/dl) 1.98 ± 0.62 2.05 0.09 2.7
Intact PTH (pg/mL) 25.1 ± 45 15.5 1.2 317.3
Serum phosphorus (mg/dl) 4.19 ± 0.63 4.1 2.7 5.9
eGFR (cc/min) 76.75 ± 26 74.5 35.4 169.8
Serum calcium (mg/dl) 9.19 ± 0.43 9 8.4 10.2
Serum alkaline phosphatase (IU/ml) 203.5 ± 66 186 91 351
Serum albumin (g/dl) 3.88 ± 0.25 3.9 3.4 4.3
BMI (kg/m2) 23.6 ± 3.4 23.7 16.04 30.4
Table 2. Frequency of gender and duration of kidney transplant in the study patients
Parameter Total H. pylori negative H. pylori positive P-value
Gender
Male 28 (56) 11 (39.2) 17 (60.8) 0.534
Female 22 (44) 8 (36.4) 14 (63.6)
Duration of kidney 
transplantation (month)
<11 4 (8) 4 (12.9) 0 0.032*
12-36 19 (38) 14 (45.1) 5 (26.3)
37-72 21 (42) 12 (38.7) 9 (47.3)
73-80 6 (12) 1 (3.2) 5 (26.3)
*P values of less than 0.05 were assumed to be significant (p<0.05).
Table 3. Demographic and biochemical data of the study patients with H. pylori and without H. pylori infection
Parameter H. pylori negative H. pylori positive P-value
Age (years) 48.2 ± 9.7 46.15 ± 11.6 0.502
Serum creatinine (mg/dl) 1.15 ± 0.2 1.72  ± 0.3 0.0001*
Serum magnesium (mg/dl) 1.75 ± 0.6 2.35 ± 0.3 0.0005*
Intact PTH (pg/mL) 28.3 ± 56 19.9 ± 14.9 0.528
Serum phosphorus (mg/dl) 4.2 ± 0.65 4.12 ± 0.61 0.560
eGFR (cc/min) 76.94 ± 28 76.4 ± 23.4 0.948
Serum calcium (mg/dl) 9.16 ± 0.43 9.23 ± 0.44 0.574
Serum alkaline phosphatase (IU/ml) 205 ± 76 201 ± 50 0.84
Serum Albumin (g/dl) 3.85 ± 0.26 3.93 ± 0.26 0.314
BMI (Kg/m2 ) 23.5 ± 3.8 23.68 ± 2.9 0.925
* P values of less than 0.05 were assumed to be significant (p<0.05).
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patients and its higher concentration in the gastric mucosa 
might improve the gastric colonization of H. pylori in 
patients on hemodialysis, but not in diabetic patients with 
various stages of kidney failure whom were not undergone 
hemodialysis yet (7,14-16). Gastric complications are 
common in patients who under hemodialysis or harbored 
renal transplantation and H. pylori infection is assumed 
to have an important role in gastrointestinal disease in 
these patients (1-5,17), on the other hand magnesium 
is principally  excreted by kidney and magnesium 
metabolism is disturbed in patients with chronic renal 
failure (18-23). In fact, elevated serum magnesium level 
can be a problem in patients on maintenance hemodialysis. 
While, the kidneys are the major route of excretion of 
magnesium from the body, increased serum magnesium 
would be expected in patients with renal failure and in 
hemodialysis patients (20-27). 
Conclusion
It is possible that, magnesium aggravates H. pylori 
infection in kidney transplant patients through the 
mechanisms like hemodialysis. However, more studies are 
necessary to prove the association of magnesium with H. 
pylori infection in renal transplant recipients and finding 
the clinical relevance of our observations. 
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